Ocera Therapeutics Announces $28 Million Private Placement
November 6, 2013Ocera will advance the clinical and nonclinical development of OCR-002, ornithine phenylacetate, for the treatment of hepatic encephalopathy and plans to enroll patients in Phase 2b for the IV form later this year and begin work on the oral form in 2014.
More »
Jim Blair’s Early Days with Amgen to New ‘Domain’
November 4, 2013Jim Blair and Domain's new investment initiatives are profiled in BioWorld Today.
More »
Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia
October 30, 2013The goals of this study, ETC-1002-008, are to compare the LDL-C lowering efficacy of ETC-1002 and to demonstrate comparable tolerability to ezetimibe, a common therapy for statin intolerance, in the treatment of patients with elevated LDL-C levels.
More »